Indefinite Delivery Contract HHSD200201035149I
Award Date
7/1/10
Last Date to Order
6/30/11
Federal Agency
CDC Office of Acquisition Services
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Clinger Cohen Act
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This federal Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, for the procurement of adult vaccines. The IDC has a total ceiling value of $105,362,800 and a period of performance through June 30, 2026. The contract is a multiple award vehicle that does not have any set-aside designations. It supports critical national immunization efforts by allowing the CDC and...
The indefinite delivery contract (IDC) 75D30120D08572 was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC for the provision of vaccines for adults. The $131,225,875 multiple award contract has a period of performance through June 30, 2021. Glaxosmithkline, a pharmaceutical company, will supply a range of vaccines and antiviral medications to support disease prevention efforts, immunization programs, and healthcare services for various U.S. government...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to supply a variety of adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The total contract ceiling value is $232,487,206.61. The contract covers the procurement of an estimated 1.5 to 3 million doses of 12 different adult vaccines, including hepatitis A, hepatitis B, hepatitis A &...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services, a civilian agency, to Merck Sharp & Dohme Corp. The contract, which has a ceiling value of $129,202,465.56, is for the delivery of adult vaccines under the 2010-2011 Adult Vaccine Contract program. The contract has a period of performance from July 1, 2010 to June 30, 2011 and was not set aside for any specific socioeconomic category. It is a multiple award...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC to procure a variety of adult vaccines over a 1-year period from July 1, 2021 to June 30, 2022. The $156,027,900 multiple award IDC contains no set-aside designation and requires delivery within 15 business days of order placement to destinations across the United States to support state health departments and immunization programs. The original solicitation...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to provide a wide range of pediatric vaccines over a period of performance from April 1, 2024 to March 31, 2025. The contract has a ceiling value of $1,334,738,300 and is part of the CDC's National Center for Immunization and Respiratory Diseases (NCIRD) effort to support pediatric immunization programs under...
The federal contract IDV award is an Indefinite Delivery Contract (IDC) awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services, a civilian federal agency, to Glaxosmithkline Holdings (Americas) Inc. The contract, identified as HHSD200200930521I, has a ceiling value of $809,252,070.00 and a period of performance from July 1, 2009 to June 30, 2010. The contract, known as VFA 2009, does not have any set-asides and was awarded as a multiple-award vehicle....
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian federal agency, to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company. The contract, valued at up to $1.489 billion, is for the procurement of standard commercial pediatric vaccines to support the Vaccines for Children (VFC) program over a 12-month period from April 1, 2025 to March 31, 2026. The solicitation was unrestricted, without any small business...
This indefinite-delivery, indefinite-quantity (IDIQ) contract was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, to Glaxosmithkline, LLC, a pharmaceutical company, for the purchase of 12 standard adult vaccines. The $172.4 million contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and does not utilize any set-asides. The vaccines, which include influenza, hepatitis, pneumococcal, and...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services, a civilian federal agency, to GlaxoSmithKline Holdings (Americas) Inc. The contract has a ceiling value of $20,661,104.25 and a period of performance from March 15, 2010 to February 28, 2011. The contract appears to be for the procurement of flu vaccine products and related services as part of the CDC's Vaccine for Children (VFC) program. While the exact scope...